Clinical Trial Update: Efficacy and Safety of Lucentis for Clinically Significant Macular Edema Secondary to Central Retinal Vein Occlusion [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the efficacy and safety of Lucentis (ranibizumab) for macular edema associated with central retinal vein occlusion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Retinal Vein Occlusion
• Macular Edema

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: University of Pecs | Conditions: Retinal Vein Occlusion, Macular Edema | Phase 2 | Status: UNKNOWN